An overview of radioimmunotherapy


In reviewing the current state of affairs in radioimmunotherapy the paper focuses on the main difficulties thus far encountered and the procedures designed to avoid or circumvent these problems. The long range β-emitters90Y and188Re have replaced131I as the isotopes currently receiving most attention for use in radioimmunotherapy, and a range of new chelators are under investigation for in vivo stability and immunogenicity. Approaches aimed at improving tumour targetting and antigen expression such as two-step pretargetting techniques, tumour necrosis treatment and cytokine pretreatment are summarised. Methods designed to improve host-Mab interactions are outlined and the need to incorporate successful ideas from current cancer therapies is emphasised.

DOI: 10.1007/BF01741338

Cite this paper

@article{Maraveyas1991AnOO, title={An overview of radioimmunotherapy}, author={Anthony Maraveyas and A. A. Epenetos}, journal={Cancer Immunology, Immunotherapy}, year={1991}, volume={34}, pages={71-73} }